These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37049787)

  • 1. Menin-MLL1 Interaction Small Molecule Inhibitors: A Potential Therapeutic Strategy for Leukemia and Cancers.
    Shi Q; Xu M; Kang Z; Zhang M; Luo Y
    Molecules; 2023 Mar; 28(7):. PubMed ID: 37049787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
    Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
    Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Menin-MLL protein-protein interaction inhibitors: a patent review (2014-2021).
    Bai H; Zhang SQ; Lei H; Wang F; Ma M; Xin M
    Expert Opin Ther Pat; 2022 May; 32(5):507-522. PubMed ID: 35202550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.
    Heikamp EB; Henrich JA; Perner F; Wong EM; Hatton C; Wen Y; Barwe SP; Gopalakrishnapillai A; Xu H; Uckelmann HJ; Takao S; Kazansky Y; Pikman Y; McGeehan GM; Kolb EA; Kentsis A; Armstrong SA
    Blood; 2022 Feb; 139(6):894-906. PubMed ID: 34582559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition.
    Soto-Feliciano YM; Sánchez-Rivera FJ; Perner F; Barrows DW; Kastenhuber ER; Ho YJ; Carroll T; Xiong Y; Anand D; Soshnev AA; Gates L; Beytagh MC; Cheon D; Gu S; Liu XS; Krivtsov AV; Meneses M; de Stanchina E; Stone RM; Armstrong SA; Lowe SW; Allis CD
    Cancer Discov; 2023 Jan; 13(1):146-169. PubMed ID: 36264143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Progress of Small Molecule Menin-MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia.
    Lei H; Zhang SQ; Fan S; Bai HR; Zhao HY; Mao S; Xin M
    J Med Chem; 2021 Nov; 64(21):15519-15533. PubMed ID: 34726905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.
    Shi A; Murai MJ; He S; Lund G; Hartley T; Purohit T; Reddy G; Chruszcz M; Grembecka J; Cierpicki T
    Blood; 2012 Nov; 120(23):4461-9. PubMed ID: 22936661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
    Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
    Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction.
    Borkin D; Klossowski S; Pollock J; Miao H; Linhares BM; Kempinska K; Jin Z; Purohit T; Wen B; He M; Sun D; Cierpicki T; Grembecka J
    J Med Chem; 2018 Jun; 61(11):4832-4850. PubMed ID: 29738674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
    Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
    J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
    Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
    Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
    Bourgeois W; Cutler JA; Aubrey BJ; Wenge DV; Perner F; Martucci C; Henrich JA; Klega K; Nowak RP; Donovan KA; Boileau M; Wen Y; Hatton C; Apazidis AA; Olsen SN; Kirmani N; Pikman Y; Pollard JA; Perry JA; Sperling AS; Ebert BL; McGeehan GM; Crompton BD; Fischer ES; Armstrong SA
    Blood; 2024 Apr; 143(15):1513-1527. PubMed ID: 38096371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction.
    Aguilar A; Zheng K; Xu T; Xu S; Huang L; Fernandez-Salas E; Liu L; Bernard D; Harvey KP; Foster C; McEachern D; Stuckey J; Chinnaswamy K; Delproposto J; Kampf JW; Wang S
    J Med Chem; 2019 Jul; 62(13):6015-6034. PubMed ID: 31244110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia.
    Klossowski S; Miao H; Kempinska K; Wu T; Purohit T; Kim E; Linhares BM; Chen D; Jih G; Perkey E; Huang H; He M; Wen B; Wang Y; Yu K; Lee SC; Danet-Desnoyers G; Trotman W; Kandarpa M; Cotton A; Abdel-Wahab O; Lei H; Dou Y; Guzman M; Peterson L; Gruber T; Choi S; Sun D; Ren P; Li LS; Liu Y; Burrows F; Maillard I; Cierpicki T; Grembecka J
    J Clin Invest; 2020 Feb; 130(2):981-997. PubMed ID: 31855575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The same pocket in menin binds both MLL and JUND but has opposite effects on transcription.
    Huang J; Gurung B; Wan B; Matkar S; Veniaminova NA; Wan K; Merchant JL; Hua X; Lei M
    Nature; 2012 Feb; 482(7386):542-6. PubMed ID: 22327296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.
    Grembecka J; He S; Shi A; Purohit T; Muntean AG; Sorenson RJ; Showalter HD; Murai MJ; Belcher AM; Hartley T; Hess JL; Cierpicki T
    Nat Chem Biol; 2012 Jan; 8(3):277-84. PubMed ID: 22286128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.
    Krivtsov AV; Evans K; Gadrey JY; Eschle BK; Hatton C; Uckelmann HJ; Ross KN; Perner F; Olsen SN; Pritchard T; McDermott L; Jones CD; Jing D; Braytee A; Chacon D; Earley E; McKeever BM; Claremon D; Gifford AJ; Lee HJ; Teicher BA; Pimanda JE; Beck D; Perry JA; Smith MA; McGeehan GM; Lock RB; Armstrong SA
    Cancer Cell; 2019 Dec; 36(6):660-673.e11. PubMed ID: 31821784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin.
    Svoboda LK; Bailey N; Van Noord RA; Krook MA; Harris A; Cramer C; Jasman B; Patel RM; Thomas D; Borkin D; Cierpicki T; Grembecka J; Lawlor ER
    Oncotarget; 2017 Jan; 8(1):458-471. PubMed ID: 27888797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.
    Yokoyama A; Somervaille TC; Smith KS; Rozenblatt-Rosen O; Meyerson M; Cleary ML
    Cell; 2005 Oct; 123(2):207-18. PubMed ID: 16239140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.